It's been a transformational year for Johnson & Johnson (NYSE: JNJ). This August, the company spun off its consumer health division into a new company called  Kenvue (NYSE: KVUE).

Now that Kenvue sells Listerine, Q-tips, and Tylenol, investors are concerned that the steady dividend raises Johnson & Johnson, or J&J, is famous for could come to an end.

Recently, J&J issued its first quarterly-earnings report since the Kenvue spinoff, and the results were better than expected. Let's look closer at the new, slimmer version of the healthcare juggernaut to see if it deserves a place in your income-generating portfolio.

Continue reading

Source Fool.com